These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 15530691)

  • 1. Comparison of antibodies directed against human respiratory syncytial virus antigens present in two commercial preparations of human immunoglobulins with different neutralizing activities.
    Sastre P; Melero JA; García-Barreno B; Palomo C
    Vaccine; 2004 Dec; 23(4):435-43. PubMed ID: 15530691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of affinity chromatography and adsorption to vaccinia virus recombinant infected cells for depletion of antibodies directed against respiratory syncytial virus glycoproteins present in a human immunoglobulin preparation.
    Sastre P; Melero JA; García-Barreno B; Palomo C
    J Med Virol; 2005 Jun; 76(2):248-55. PubMed ID: 15834867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased susceptibility of human respiratory syncytial virus to neutralization by anti-fusion protein antibodies on adaptation to replication in cell culture.
    Marsh R; Connor A; Gias E; Toms GL
    J Med Virol; 2007 Jun; 79(6):829-37. PubMed ID: 17457900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of the binding of monoclonal and polyclonal antibodies to the glycoproteins of antigenic variants of human respiratory syncytial virus by surface plasmon resonance.
    McGill A; Marsh R; Craft AW; Toms GL
    J Immunol Methods; 2005 Feb; 297(1-2):143-52. PubMed ID: 15777938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of anti-human respiratory syncytial virus antibodies over three consecutive years in a healthy adult population.
    Chala SR; García-Barreno B; Melero JA; Palomo C
    J Med Virol; 2003 Oct; 71(2):298-304. PubMed ID: 12938206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the antibody specificities of human convalescent-phase sera against the attachment (G) protein of human respiratory syncytial virus: influence of strain variation and carbohydrate side chains.
    Palomo C; Cane PA; Melero JA
    J Med Virol; 2000 Apr; 60(4):468-74. PubMed ID: 10686032
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human monoclonal antibodies isolated from spontaneous Epstein-Barr virus-transformed tumors of Hu-SPL-SCID mice and specific for fusion protein display broad neutralizing activity toward respiratory syncytial virus.
    Chamat S; Walsh EE; Anderson D; Osta M; Awaraji C; Pan LZ; Ochi J; Shuey S; Brams P
    J Infect Dis; 1999 Aug; 180(2):268-77. PubMed ID: 10395839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Host cell effect upon glycosylation and antigenicity of human respiratory syncytial virus G glycoprotein.
    García-Beato R; Martínez I; Francí C; Real FX; García-Barreno B; Melero JA
    Virology; 1996 Jul; 221(2):301-9. PubMed ID: 8661440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum antibody response to respiratory syncytial virus F and N proteins in two populations at high risk of infection: children and elderly.
    Sastre P; Cusi MG; Manoha C; Schildgen O; Ruiz T; Vela C; Rueda P
    J Virol Methods; 2010 Sep; 168(1-2):170-6. PubMed ID: 20488207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isolation of a neutralizing human RSV antibody from a dominant, non-neutralizing immune repertoire by epitope-blocked panning.
    Tsui P; Tornetta MA; Ames RS; Bankosky BC; Griego S; Silverman C; Porter T; Moore G; Sweet RW
    J Immunol; 1996 Jul; 157(2):772-80. PubMed ID: 8752928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between the loss of neutralizing antibody binding and fusion activity of the F protein of human respiratory syncytial virus.
    Liu C; Day ND; Branigan PJ; Gutshall LL; Sarisky RT; Del Vecchio AM
    Virol J; 2007 Jul; 4():71. PubMed ID: 17623075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potent high-affinity antibodies for treatment and prophylaxis of respiratory syncytial virus derived from B cells of infected patients.
    Collarini EJ; Lee FE; Foord O; Park M; Sperinde G; Wu H; Harriman WD; Carroll SF; Ellsworth SL; Anderson LJ; Tripp RA; Walsh EE; Keyt BA; Kauvar LM
    J Immunol; 2009 Nov; 183(10):6338-45. PubMed ID: 19841167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of an antigenic site that contains a dominant, type-specific neutralization determinant on the envelope protein domain III (ED3) of dengue 2 virus.
    Gromowski GD; Barrett AD
    Virology; 2007 Sep; 366(2):349-60. PubMed ID: 17719070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced neutralization of human respiratory syncytial virus by mixtures of monoclonal antibodies to the attachment (G) glycoprotein.
    Martínez I; Melero JA
    J Gen Virol; 1998 Sep; 79 ( Pt 9)():2215-20. PubMed ID: 9747731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention.
    Magro M; Mas V; Chappell K; Vázquez M; Cano O; Luque D; Terrón MC; Melero JA; Palomo C
    Proc Natl Acad Sci U S A; 2012 Feb; 109(8):3089-94. PubMed ID: 22323598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The standardization of an ultramicro ELISA assay for the detection of IgG antibodies to the respiratory syncytial virus].
    Savón C; Laferté J; Goyenechea A; Valdivia A; Morier L; Tejeiro Y
    Rev Cubana Med Trop; 1996; 48(3):161-2. PubMed ID: 9805041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generation and epitope mapping of a sub-group cross-reactive anti-respiratory syncytial virus G glycoprotein monoclonal antibody which is protective in vivo.
    Robinson MJ; Tan CS; Fenwick F; Chambers CJ; Routledge EG; Toms GL
    J Med Virol; 2014 Jul; 86(7):1267-77. PubMed ID: 24415460
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of two antigenic sites recognized by neutralizing monoclonal antibodies directed against the fusion glycoprotein of human respiratory syncytial virus.
    Arbiza J; Taylor G; López JA; Furze J; Wyld S; Whyte P; Stott EJ; Wertz G; Sullender W; Trudel M
    J Gen Virol; 1992 Sep; 73 ( Pt 9)():2225-34. PubMed ID: 1383404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The antibodies directed against N-terminal heptad-repeat peptide of hRSV fusion protein and its analog-5-Helix inhibit virus infection in vitro.
    Ni L; Zhao L; Gao GF; Qian Y; Tien P
    Biochem Biophys Res Commun; 2005 Jun; 331(4):1358-64. PubMed ID: 15883025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of human respiratory syncytial virus genotype specific antibody responses in infants.
    McGill A; Greensill J; Marsh R; Craft AW; Toms GL
    J Med Virol; 2004 Nov; 74(3):492-8. PubMed ID: 15368511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.